In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis

Antimicrob Agents Chemother. 2005 Jun;49(6):2510-1. doi: 10.1128/AAC.49.6.2510-2511.2005.

Abstract

Doripenem 50% inhibitory concentrations (MIC50) and 90% inhibitory concentrations (MIC90) for multidrug-resistant strains of mucoid Pseudomonas aeruginosa (n=200 strains), nonmucoid P. aeruginosa (n=200), and Burkholderia cepacia complex (n=200) isolated from patients with cystic fibrosis were 8 and 32, 8 and 64, and 8 and 32 microg/ml, respectively. Doripenem had somewhat better activity than established antimicrobial agents.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Burkholderia Infections / microbiology
  • Burkholderia cepacia complex / drug effects*
  • Burkholderia cepacia complex / isolation & purification
  • Carbapenems / pharmacology*
  • Cystic Fibrosis / microbiology*
  • Doripenem
  • Drug Resistance, Multiple, Bacterial*
  • Humans
  • Microbial Sensitivity Tests
  • Pseudomonas Infections / microbiology
  • Pseudomonas aeruginosa / drug effects*
  • Pseudomonas aeruginosa / isolation & purification

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • Doripenem